ASH 2018 | Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath from the Institute of Cancer Research and Royal Marsden hospital, London, UK discusses the outcome of the UK-based Myeloma XI trial (NCT01554852). Dr Pawlyn firstly explains how the use of a quadruplet regimen (carfilzomib, cyclophosphamide, lenalidomide and dexamethasone) in the treatment of newly diagnosed multiple myeloma brought about increased progression-free survival compared to the standard triplet regimen used (thalidomide or lenalidomide combined with cyclophosphamide and dexamethasone). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Pawlyn goes on to discuss the results of an exploratory analysis of the Myeloma XI trial, which found that the same clinical outcome was reached in patients requiring four treatment cycles as opposed to those needing more to reach the maximum response.
